Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma has enhanced its clinical and financial position through an $8 million financing and the advancement of its EB103 therapy into the Phase II trial stage, indicating strong operational momentum. The company has received positive recommendations from an independent Data and Safety Monitoring Board, which suggests that the STARLIGHT-1 trial could lead to significant advancements in treatment efficacy and safety data for broader patient populations. Additionally, the innovative Artemis Technology platform positions Estrella to unlock new market opportunities in immunology and solid tumor treatment, further bolstering its growth potential as its clinical programs progress.

Bears say

Estrella Immunopharma's stock has experienced a decline that raises concerns about potential future dilution, suggesting challenges in maintaining investor confidence. The company's management has indicated that strategic priorities, including updates on partnerships and pipeline prioritization, will be addressed in an upcoming shareholders meeting, but uncertainties about execution remain. Furthermore, the adjustment of the target price from $16.0 to $8.0 reflects a more conservative stance in light of these developments and highlights the growing apprehension surrounding the company's financial outlook.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.